(what must be controlled in materials).

Practical view: CQAs are product outcomes, CPPs are process levers, and CMAs are material drivers of variability.

How CMAs Are Identified (Practical Approach)

CMAs are usually identified by combining material science knowledge, risk tools, and development evidence:

• Start from CQAs: list what product attributes are most critical.
• Identify material-related risks: which material properties could affect those CQAs?
• Use risk assessment: assess severity, likelihood, detectability for material variability.
• Confirm with evidence: development studies, DOE, scale-up experience, supplier history.
• Decide control method: specification limits, supplier controls, incoming tests, COA verification.

CMAs are not “all material specs.” They are the attributes that realistically change process performance or product quality if they drift.

Common CMA Examples (API)

For APIs, CMAs often relate to solid-state and physical properties that strongly influence performance:

• Particle size distribution (PSD): affects dissolution, blending, content uniformity
• Polymorphic form: affects solubility, stability, bioavailability
• Crystallinity/amorphous content: affects dissolution and stability
• Specific surface area: affects dissolution and reactivity
• Moisture content: affects stability and processing behavior
• Bulk density and flowability: affects feeding, compression, uniformity
• Residual solvents / impurities: affects safety, stability, and compliance

Common CMA Examples (Excipients)

Excipient variability is a frequent “silent cause” of batch performance issues. Typical excipient CMAs include:

• Grade and functional performance: binder viscosity grade, disintegrant performance
• Moisture content: affects granulation and stability
• Particle size / PSD: affects blending and dissolution
• Compressibility: affects hardness/friability at given compression force
• pH (for certain excipients): affects stability or solubility
• Microbial limits (for certain materials): impacts bioburden control

CMAs in Sterile Manufacturing (Often Overlooked)

For sterile products, CMAs can include:

• Filter attributes: pore rating, compatibility, extractables risk profile
• Primary packaging attributes: vial/stopper properties, coating, particulate shedding
• Water quality attributes: TOC, conductivity, microbial/endotoxin levels
• Gas quality attributes: compressed air/nitrogen purity and contamination risks

Here, material attributes directly affect sterility assurance, particulate control, and patient safety.

How CMAs Link to Control Strategy (What “Control” Really Means)

Once a CMA is identified, you must define how it will be controlled. Typical control options include:

• Material specifications: defined acceptance limits and test methods
• Supplier qualification: audits, quality agreements, change notification expectations
• Incoming material testing: COA verification, identity testing, additional critical tests
• Material handling controls: storage conditions, FIFO, humidity control, hold time limits
• Process compensation: adjust process settings when a CMA varies (only when justified)

A strong approach is to control CMAs at the material level whenever feasible rather than “fixing” variability during manufacturing.

Mini Example: CMA Impact on a CQA

Consider dissolution as a CQA for an immediate-release tablet. If API particle size distribution shifts to larger particles, dissolution can slow down. If PSD is a CMA, then controlling PSD (spec limit + supplier controls + incoming checks) helps protect dissolution. If PSD is not controlled, teams may see unexplained dissolution variability even when process parameters appear consistent.

Common CMA Mistakes (Audit Traps)

• Ignoring supplier variability: assuming all lots behave the same without evidence.
• Over-reliance on COA: not verifying critical attributes for high-risk materials.
• CMAs not linked to CQAs: criticality not justified with a quality impact rationale.
• Specs too wide: acceptance limits allow variability that harms performance.
• No control plan for changes: material changes introduced without proper assessment.

Audit-Ready Talking Points

• CMAs are selected using scientific knowledge and risk assessment
• CMAs are linked to CQAs and justified with evidence or rationale
• Material controls (specs, supplier oversight, incoming testing) are documented and risk-based
• Material change impacts are assessed and controlled
• CMAs are reviewed as process knowledge grows and during investigations

FAQs

What does CMA stand for in pharma?

CMA stands for Critical Material Attribute.

Are CMAs only for APIs?

No. CMAs can apply to APIs, excipients, solvents, gases, water, filters, and even primary packaging components—any input material that can affect product quality.

How do you decide an attribute is critical?

By assessing whether variation in that attribute can reasonably impact CQAs (safety, efficacy, performance), using risk assessment and supporting data.

How are CMAs controlled?

Common controls include supplier qualification, specifications, incoming testing, storage/handling controls, and controlled assessment of any material changes.

What’s a common CMA-related audit finding?

Weak justification and weak controls—critical material variability not assessed, and over-reliance on supplier COAs without risk-based verification.